These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1102 related articles for article (PubMed ID: 27757953)

  • 21. Non-invasive biomarkers in non-alcoholic steatohepatitis-induced hepatocellular carcinoma.
    Voiculescu M; Nanau RM; Neuman MG
    J Gastrointestin Liver Dis; 2014 Dec; 23(4):425-9. PubMed ID: 25532002
    [TBL] [Abstract][Full Text] [Related]  

  • 22. TUBB4B is a novel therapeutic target in non-alcoholic fatty liver disease-associated hepatocellular carcinoma.
    Yang Z; Gao S; Wong CC; Liu W; Chen H; Shang H; Wu ZY; Xu L; Zhang X; Wong N; Kuang M; Yu J
    J Pathol; 2023 May; 260(1):71-83. PubMed ID: 36787097
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Predicting Non-Alcoholic Fatty Liver Disease Progression and Immune Deregulations by Specific Gene Expression Patterns.
    Zeng F; Zhang Y; Han X; Zeng M; Gao Y; Weng J
    Front Immunol; 2020; 11():609900. PubMed ID: 33574818
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A Mouse Model of Hepatocellular Carcinoma Induced by Streptozotocin and High-Fat Diet.
    Motiño O; Li S; Lambertucci F; Anagnostopoulos G; Montégut L; Nogueira-Recalde U; Chen H; Maiuri MC; Kroemer G; Martins I
    Methods Mol Biol; 2024; 2769():67-75. PubMed ID: 38315389
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Translational approaches: from fatty liver to non-alcoholic steatohepatitis.
    Rosso N; Chavez-Tapia NC; Tiribelli C; Bellentani S
    World J Gastroenterol; 2014 Jul; 20(27):9038-49. PubMed ID: 25083077
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Research advances in the pathogenesis of non-alcoholic fatty liver disease-associated liver cancer].
    Huang W; Zhang XX
    Zhonghua Gan Zang Bing Za Zhi; 2017 Feb; 25(2):157-160. PubMed ID: 28297806
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Hepatocellular carcinoma in patients with non-alcoholic fatty liver disease.
    Wong CR; Nguyen MH; Lim JK
    World J Gastroenterol; 2016 Oct; 22(37):8294-8303. PubMed ID: 27729736
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Hepatocellular carcinoma development in non-alcoholic fatty liver disease and non-alcoholic steatohepatitis. Is it going to be the "Plague" of the 21st century? A literature review focusing on pathogenesis, prevention and treatment.
    Argyrou C; Moris D; Vernadakis S
    J BUON; 2017; 22(1):6-20. PubMed ID: 28365930
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Peroxisomal β-oxidation regulates whole body metabolism, inflammatory vigor, and pathogenesis of nonalcoholic fatty liver disease.
    Moreno-Fernandez ME; Giles DA; Stankiewicz TE; Sheridan R; Karns R; Cappelletti M; Lampe K; Mukherjee R; Sina C; Sallese A; Bridges JP; Hogan SP; Aronow BJ; Hoebe K; Divanovic S
    JCI Insight; 2018 Mar; 3(6):. PubMed ID: 29563328
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Fatty Liver Disease and Hepatocellular Carcinoma: The Pathologist's View.
    Tiniakos DG; Maurício J; Reeves HL
    Adv Exp Med Biol; 2018; 1032():55-69. PubMed ID: 30362090
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Genetic polymorphisms and oxidative stress in non-alcoholic steatohepatitis (NASH): A mini review.
    Oliveira CP; Stefano JT
    Clin Res Hepatol Gastroenterol; 2015 Sep; 39 Suppl 1():S35-40. PubMed ID: 26160475
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Autophagy, NAFLD and NAFLD-Related HCC.
    Wu WKK; Zhang L; Chan MTV
    Adv Exp Med Biol; 2018; 1061():127-138. PubMed ID: 29956211
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Epidemiology and Etiologic Associations of Non-alcoholic Fatty Liver Disease and Associated HCC.
    Liu K; McCaughan GW
    Adv Exp Med Biol; 2018; 1061():3-18. PubMed ID: 29956203
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The Natural Course of Non-Alcoholic Fatty Liver Disease.
    Calzadilla Bertot L; Adams LA
    Int J Mol Sci; 2016 May; 17(5):. PubMed ID: 27213358
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Long non-coding RNAs as modulators and therapeutic targets in non-alcoholic fatty liver disease (NAFLD).
    Tao Q; Xie J; Wu Y; Jin Y
    Gastroenterol Hepatol; 2024 May; 47(5):506-516. PubMed ID: 37806343
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Systems biology approaches for studying the pathogenesis of non-alcoholic fatty liver disease.
    Fisher CP; Kierzek AM; Plant NJ; Moore JB
    World J Gastroenterol; 2014 Nov; 20(41):15070-8. PubMed ID: 25386055
    [TBL] [Abstract][Full Text] [Related]  

  • 37. MicroRNAs in the pathogenesis and treatment of progressive liver injury in NAFLD and liver fibrosis.
    Su Q; Kumar V; Sud N; Mahato RI
    Adv Drug Deliv Rev; 2018 Apr; 129():54-63. PubMed ID: 29391222
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Phenotypic Alteration of Hepatocytes in Non-Alcoholic Fatty Liver Disease.
    Lakhani HV; Sharma D; Dodrill MW; Nawab A; Sharma N; Cottrill CL; Shapiro JI; Sodhi K
    Int J Med Sci; 2018; 15(14):1591-1599. PubMed ID: 30588181
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Glucocorticoids and non-alcoholic fatty liver disease.
    Woods CP; Hazlehurst JM; Tomlinson JW
    J Steroid Biochem Mol Biol; 2015 Nov; 154():94-103. PubMed ID: 26241028
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Non-alcoholic fatty liver disease and hepatocellular carcinoma - 2016].
    Pár A; Pár G
    Orv Hetil; 2016 Jun; 157(25):987-94. PubMed ID: 27287838
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 56.